Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045214 | 0.82 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3056041 | 0.77 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3056259 | 0.77 | USP30 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3049823 | 0.76 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8095955 | 0.74 | NR2E1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3040146 | 0.72 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL757546 | 0.69 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3526697 | 0.69 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7921146 | 0.68 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7923905 | 0.67 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008156580-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | BACE1, PSEN1, PSEN2 | PSEN1 2/4885PSEN2 3/4885APH1B 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.